Tag: Candidate

Scientists find evidence of exotic state of matter in candidate material for quantum computers

Scientists find evidence of exotic state of matter in candidate material for quantum computers
An illustration of the crystal structure of ruthenium trichloride showing the simple honeycomb lattice of ruthenium ions and chlorine ions. The twisted octahedra formed by chlorine around the electron spin of each ruthenium atom are mirror images of each other. This twist is key to the compound’s unusual behavior, which is evidence that it may contain an example of a quantum spin liquid. Credit: Courtesy of Arkady Shekhter/ National High Magnetic Field Laboratory

Using a novel technique, scientists working at the Florida State University-headquartered National High Magnetic Field Laboratory have found evidence for a quantum spin liquid, a state of matter that is promising as a building block for the quantum computers of tomorrow.


Researchers discovered the exciting behavior while studying the so-called electron spins in the compound ruthenium trichloride. Their findings, published today in the journal Nature Physics , show that electron spins interact across the material, effectively lowering

Read More

TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate

  •  Initiating clinical trials to evaluate investigational toll-like receptor 9 agonist, SD-101, in patients with uveal melanoma liver metastases followed by three additional indications.

  • Aspiring to overcome the challenges of treating patients with solid tumors through our multi-pronged approach to stimulate the immune system and deliver immuno-oncology therapies directly to the site of the disease, with the goal of improving the therapeutic index

  • Working to redefine the treatment of hard-to-treat solid tumors in the liver or pancreas by combining TriSalus’ proprietary FDA cleared intravascular, regional drug delivery technology for liver and pancreatic infusion with investigational SD-101 and standard of care therapy

TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors, announced today its therapeutic clinical development strategy following the successful acquisition of SD-101, an investigational IND-ready immunotherapy, from Dynavax Technologies on August 3, 2020.

SD-101 is an investigational toll-like receptor 9 (TLR9) agonist

Read More